Patent · US Active

Terminally modified RNA

US9597380B2 · kind B2 · utility

125Cited by

404References

13Claims

0Family size

Assignee

ModernaTX, Inc. · US

Inventors

Tirtha Chakraborty · Medford, US
Stephane Bancel · Cambridge, US
Stephen Hoge · Brookline, US
Atanu Roy · Stoneham, US
Antonin de Fougerolles · Waterloo, BE
Noubar B. Afeyan · Lexington, US

Key dates

Filing date	Oct 2, 2013
Grant date	Mar 21, 2017
Priority date	—
Expiry date	Oct 2, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N15/67
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.